Celanese Series A: MGI Tech Secures CE Mark for Revolutionary DNBSEQ-T1+ Genetic Sequencer
- MGI Tech receives CE mark for DNBSEQ-T1+, enabling entry into the European market for research and clinical use.
- The DNBSEQ-T1+ can perform paired-end 150 sequencing in 24 hours with Q40 accuracy, enhancing operational efficiency.
- MGI aims to advance genomics research and precision medicine through innovative sequencing tools amid growing European demand.
MGI Tech's CE Mark Approval: A Leap Forward in Genetic Sequencing
MGI Tech Co., Ltd. achieves a significant milestone by obtaining the CE mark for its mid-throughput sequencer, the DNBSEQ-T1+, thereby facilitating its entry into the European market for both research and clinical applications. This development marks an important step in MGI's global expansion strategy, as the company seeks to enhance its offering in the rapidly evolving field of genomics. The DNBSEQ-T1+, first introduced at the AGBT 2025 conference, stands out as a cutting-edge benchtop genetic sequencer, capable of executing a paired-end 150 sequencing workflow in just 24 hours while delivering Q40 accuracy. Such performance positions it prominently among the fastest mid-throughput sequencers available today.
The T1+ features versatile flow cell formats, accommodating two to four addressable lanes per cell, with a data output capacity ranging from 25 to 1,200 gigabases. This flexibility allows laboratories to execute a wide array of independent experiments on a single platform, significantly enhancing operational efficiency. Additional features include integrated auto-DNB making and loading systems, as well as a built-in bioinformatics module, which streamlines user experience and increases productivity. Duncan Yu, President of MGI, underscores the importance of the CE mark, asserting that it validates the T1+'s compliance with European standards and enhances its potential to propel advancements in genomics research, particularly in the areas of precision medicine and oncology.
The T1+ garnered considerable attention during its debut at the European Society of Human Genetics (ESHG) exhibition, where attendees expressed keen interest in its practical applications. The positive reception highlights not only the innovative capabilities of MGI's technology but also the growing demand for efficient genetic sequencing tools in Europe. Founded in 2016, MGI remains committed to advancing life sciences through the development of innovative tools and technologies, serving customers across diverse sectors, including healthcare, agriculture, and beyond.
In addition to the T1+'s debut, MGI continues to reinforce its status as a leader in the life sciences sector by expanding its product portfolio. The company’s focus on research, manufacturing, and sales of instruments and reagents positions it well to capitalize on emerging opportunities in genomics. As the demand for precision medicine grows, MGI is poised to play a crucial role in supporting researchers and clinicians throughout Europe and beyond. The successful launch of the DNBSEQ-T1+ is expected to enhance the company's competitive advantage and facilitate its ongoing global outreach.
